Press ReleasesGerman Cannabis Company Continues Its Strong Growth - A...

German Cannabis Company Continues Its Strong Growth – A Further Seven Million Euros For SynBiotic SE


 THE specialist cannabis company SynBiotic SE has successfully completed another capital increase. 334,000 new shares were placed with institutional investors at an issue price of EUR 21 per share. 

With the proceeds of around €7m, the listed company intends to finance further growth and expansion. A large part of the proceeds from the issue – possibly in tandem with targeted use of the company’s own shares – is to be dedicated to strategic acquisitions. 

SynBiotic SE is the first listed specialist cannabis company in Germany. Since its initial listing in November 2019, it has raised more than €13m and invested early in the pan-European expansion of business, new products and more intensive marketing. 

CEO Lars Müller says: “A look at the outgoing year shows that we have set a breath-taking pace with the growth of SynBiotic SE. The new government in Germany is now giving us additional tailwind. The details are not yet known, but we expect a significant step forward in terms of legalization and commercialization. 

“As the market leader in Germany, we are ideally positioned to transform this tailwind into expanding market shares and increasing sales. At the same time, we want to accelerate growth in other European countries and establish ourselves as the European market leader.” 

About SynBiotic SE 

SynBiotic SE is the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions to major social problems such as pain, sleep-disorders and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and distributes pharmaceutical and dietary supplements as well as cosmetic products under its own brands. 

Latest news

Treasury Should “Unlock” Cannabis Economic Benefits, Says CIC

PRESS RELEASE THE Treasury has been urged to ”unlock the very significant economic potential” of the medical cannabis, hemp, and...

Bloomwell Group Closes Multi-Million Euro Growth Capital Round With Leading US Venture Capital Investors, And Award-Winning Actor, Moritz Bleibtreu

PRESS RELEASE FRANKFURT-based medical cannabis holding company Bloomwell Group (“Bloomwell,” “Bloomwell Group,” or the “Company”) has closed a significant multi-million Euro funding...

Norway Hosts First Public Meeting On Medical Cannabis Amid ‘Early First Steps’ Towards Potential Reform

NORWAY, one of the most cautious states in Europe when it comes to cannabis liberalisation, recently held a public...

Cutbill Jacoby PR Launches To Focus On Emerging Industries

PRESS RELEASE Cutbill Jacoby, a London-based Communications and PR agency for emerging industries, launches to initially service the fast-growing industrial...

Sana Healthcare Becomes Script Assist: Company Rebrands To Focus On Innovative Problem-Solving Platform

SANA Healthcare will from today be known as Script Assist after the company’s innovative platform which provides clinicians with...

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly by its former managing director Philip Small, who left the...

Must read

Love Hemp ‘Rigorously Refutes’ Allegations Of Fraud Levelled By Former Managing Director

LOVE Hemp has responded to damning allegations made publicly...

You might also likeRELATED
Recommended to you